Vimarsana
Biggest News Aggregation in the World

Jonathanc Fox News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathanc Fox. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathanc Fox Today - Breaking & Trending Today

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM - Vimarsana News

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM

Treatment-Related Early Increase in Serum TTR is Associated With Lower Cardiovascular Mortality in ATTR-CM: Insights From ATTRibute-CM Amrut...

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy - Vimarsana News

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy

Early Increase in Serum Transthyretin Level Is an Independent Predictor of Improved Survival in ATTR Cardiomyopathy: Insights From Acoramidis Phase 3 Study ATTRibute-CM ...

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients - Vimarsana News

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients

Higher Risk of Mortality in Previously Hospitalized Patients: Insights From ATTRibute-CM Ahmad Masri1, Michele Emdin2, Keyur Shah3, Kunal Bhatt4,...

Edgewise Therapeutics (NASDAQ:EWTX) Research Coverage Started at Piper Sandler - Vimarsana News

Edgewise Therapeutics (NASDAQ:EWTX) Research Coverage Started at Piper Sandler

Piper Sandler assumed coverage on shares of Edgewise Therapeutics (NASDAQ:EWTX – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $48.00 price target on the stock. Separately, Wedbush dropped their target price on Edgewise Therapeutics from $27.00 to $23.00 and set an […]

FY2023 EPS Estimates for Edgewise Therapeutics, Inc. Increased by Wedbush (NASDAQ:EWTX) - Vimarsana News

FY2023 EPS Estimates for Edgewise Therapeutics, Inc. Increased by Wedbush (NASDAQ:EWTX)

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) – Equities researchers at Wedbush lifted their FY2023 earnings per share (EPS) estimates for shares of Edgewise Therapeutics in a report issued on Monday, January 22nd. Wedbush analyst L. Chico now expects that the company will earn ($1.50) per share for the year, up from their prior forecast […]